2020
Repeat tick exposure elicits distinct immune responses in guinea pigs and mice
Kurokawa C, Narasimhan S, Vidyarthi A, Booth CJ, Mehta S, Meister L, Diktas H, Strank N, Lynn GE, DePonte K, Craft J, Fikrig E. Repeat tick exposure elicits distinct immune responses in guinea pigs and mice. Ticks And Tick-borne Diseases 2020, 11: 101529. PMID: 32993942, PMCID: PMC7530331, DOI: 10.1016/j.ttbdis.2020.101529.Peer-Reviewed Original ResearchConceptsGuinea pigsElicit distinct immune responsesDistinct immune responsesGuinea pig modelLocal blood flowImmune animalsInflammatory pathwaysTick rejectionMechanisms of resistanceImmune responseMouse modelVaccine candidatesBite siteBlood flowPig modelCoagulation pathwayComplement activationAcquired ResistanceProtective antigenTick detachmentTick proteinsBlood mealMiceTick infestationRNA sequencing
2019
Loss of the TAM Receptor Axl Ameliorates Severe Zika Virus Pathogenesis and Reduces Apoptosis in Microglia
Hastings AK, Hastings K, Uraki R, Hwang J, Gaitsch H, Dhaliwal K, Williamson E, Fikrig E. Loss of the TAM Receptor Axl Ameliorates Severe Zika Virus Pathogenesis and Reduces Apoptosis in Microglia. IScience 2019, 13: 339-350. PMID: 30884311, PMCID: PMC6424058, DOI: 10.1016/j.isci.2019.03.003.Peer-Reviewed Original ResearchZIKV infectionZIKV pathogenesisVirus infectionAxl-deficient miceZika virus pathogenesisRole of AxlZika virus infectionAlpha/beta receptorTAM receptor AxlInterferon alpha/beta receptorTAM receptorsVirus pathogenesisMouse modelEntry receptorBeta receptorsReceptor AxlViral infectionAXL inhibitorAxl receptorInfectionPathogenesisAxlMiceLess apoptosisReceptorsModeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor
Marín-Lopez A, Calvo-Pinilla E, Moreno S, Utrilla-Trigo S, Nogales A, Brun A, Fikrig E, Ortego J. Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor. Viruses 2019, 11: 35. PMID: 30625992, PMCID: PMC6356211, DOI: 10.3390/v11010035.Peer-Reviewed Original ResearchConceptsMouse modelAnimal modelsArbovirus infectionInterferon α/β receptorAlpha/beta receptorAppropriate animal modelsNatural hostInterferon alpha/beta receptorSafe therapyProtective efficacyArboviral infectionsImmune responseAdult miceBeta receptorsNew vaccinesDisease pathogenesisExtrapolation of findingsΒ receptorExperimental infectionBiosafety level 3MiceInfectionStatistical significanceVirusPathogenesis
2015
Frostbite Protection in Mice Expressing an Antifreeze Glycoprotein
Heisig M, Mattessich S, Rembisz A, Acar A, Shapiro M, Booth CJ, Neelakanta G, Fikrig E. Frostbite Protection in Mice Expressing an Antifreeze Glycoprotein. PLOS ONE 2015, 10: e0116562. PMID: 25714402, PMCID: PMC4340617, DOI: 10.1371/journal.pone.0116562.Peer-Reviewed Original ResearchConceptsAnti-freeze glycoproteinAnti-freeze proteinsTransgenic Drosophila modelReduced cell deathDiverse speciesMammalian cellsDrosophila modelCold stressIAFGPMammalian tissuesCold shockCell deathCold hardinessDiverse mechanismsTick hostsTransgenic mouse modelPrevents tissue damagePrevention of frostbiteCold temperaturesAntifreeze glycoproteinsTransgenic miceGlycoproteinNorthern latitudesProtective functionMouse model
2012
Antibodies against the Envelope Glycoprotein Promote Infectivity of Immature Dengue Virus Serotype 2
da Silva Voorham JM, Rodenhuis-Zybert IA, Nuñez N, Colpitts TM, van der Ende-Metselaar H, Fikrig E, Diamond MS, Wilschut J, Smit JM. Antibodies against the Envelope Glycoprotein Promote Infectivity of Immature Dengue Virus Serotype 2. PLOS ONE 2012, 7: e29957. PMID: 22431958, PMCID: PMC3303773, DOI: 10.1371/journal.pone.0029957.Peer-Reviewed Original ResearchConceptsAntibody-dependent enhancementImmature DENVAnti-prM antibodiesStructural proteins prMSevere dengue diseaseDengue virus antibodiesDengue virus serotype 2Dose-dependent mannerImmature particlesStandard virus preparationsVirus preparationsVirus antibodiesPrecursor membrane proteinVirus serotype 2Lethal infectionMouse modelDengue diseaseImmune serumDENV particlesProtein prMInfection studiesAntibodiesEnhanced infectivityInfectionSerotype 2The Circadian Clock Controls Toll-like Receptor 9-Mediated Innate and Adaptive Immunity
Silver AC, Arjona A, Walker WE, Fikrig E. The Circadian Clock Controls Toll-like Receptor 9-Mediated Innate and Adaptive Immunity. Immunity 2012, 36: 251-261. PMID: 22342842, PMCID: PMC3315694, DOI: 10.1016/j.immuni.2011.12.017.Peer-Reviewed Original ResearchConceptsToll-like receptor 9Receptor 9Adaptive immune responsesInnate immune systemCircadian molecular clockSepsis inductionTLR9 expressionTLR9 ligandsImmune responseVaccination modelAdaptive immunityMouse modelImmune systemDisease severityHomeostatic processesCircadian rhythmBiologic processesDirect molecular linkMolecular linkRhythmSepsisImmunotherapyImmunoprophylaxisExpressionInnate
2011
Circadian rhythms influence disease severity in a mouse model of sepsis (110.9)
Walker W, Bozzi A, Fikrig E. Circadian rhythms influence disease severity in a mouse model of sepsis (110.9). The Journal Of Immunology 2011, 186: 110.9-110.9. DOI: 10.4049/jimmunol.186.supp.110.9.Peer-Reviewed Original ResearchInflammatory responseMouse modelCircadian rhythmSerum proinflammatory cytokinesPuncture (CLP) mouse modelRisk of mortalitySeptic patientsSepsis inductionCecal ligationSepsis phenotypesEarly mortalityProinflammatory cytokinesSevere hypothermiaDisease scoreCLP modelDisease severitySepsisCreatine kinaseMortalityPatientsMiceRhythmSeverityTime 19Mammalian physiology
2010
TLR9-Targeted Biodegradable Nanoparticles as Immunization Vectors Protect against West Nile Encephalitis
Demento SL, Bonafé N, Cui W, Kaech SM, Caplan MJ, Fikrig E, Ledizet M, Fahmy TM. TLR9-Targeted Biodegradable Nanoparticles as Immunization Vectors Protect against West Nile Encephalitis. The Journal Of Immunology 2010, 185: 2989-2997. PMID: 20660705, PMCID: PMC3753007, DOI: 10.4049/jimmunol.1000768.Peer-Reviewed Original ResearchConceptsBiodegradable nanoparticlesUnmodified nanoparticlesImmune responseNanoparticlesCell-mediated immune responsesRobust humoral responseTh1 immune responseEffector T cellsAg-specific lymphocytesTh2-biased responsesAdjuvant aluminum hydroxideWest Nile encephalitisVirus encephalitisWest Nile virusAgHumoral responseCpG oligodeoxynucleotideT cellsMouse modelLive virusInfectious agentsProtein AgVaccine developmentWN virusNile virus
2004
CXCR2 Blockade Influences Anaplasma phagocytophilum Propagation but Not Histopathology in the Mouse Model of Human Granulocytic Anaplasmosis
Scorpio DG, Akkoyunlu M, Fikrig E, Dumler JS. CXCR2 Blockade Influences Anaplasma phagocytophilum Propagation but Not Histopathology in the Mouse Model of Human Granulocytic Anaplasmosis. MSphere 2004, 11: 963-968. PMID: 15358660, PMCID: PMC515272, DOI: 10.1128/cdli.11.5.963-968.2004.Peer-Reviewed Original ResearchConceptsHuman granulocytic anaplasmosisControl miceGranulocytic anaplasmosisC3H-scid miceInfected cellsTissue loadsObligate intracellular bacteriumNeutrophil recruitmentNeutrophil secretionAntibody blockadeChemokine inductionHepatic pathologyLiver histopathologyInterleukin-8Tissue injuryMouse modelControl animalsDay 14Intracellular bacteriumMiceInfectionAnaplasma phagocytophilumA. phagocytophilumHistopathologyNeutrophils
2002
Superoxide Anion Production during Anaplasma phagocytophila Infection
Wang T, Malawista SE, Pal U, Grey M, Meek J, Akkoyunlu M, Thomas V, Fikrig E. Superoxide Anion Production during Anaplasma phagocytophila Infection. The Journal Of Infectious Diseases 2002, 186: 274-280. PMID: 12134266, DOI: 10.1086/341451.Peer-Reviewed Original ResearchConceptsChronic granulomatous diseaseRespiratory burstA. phagocytophilaRespiratory burst inhibitionNitroblue tetrazoliumPopulation of neutrophilsSuperoxide anion productionInfected miceGranulomatous diseaseMouse modelUse of assaysPolymorphonuclear leukocytesUninfected animalsAnaplasma phagocytophilaAnion productionNeutrophilsInfectionHL-60 cellsIndividual cell basisAssaysCell basisCellsPatientsLeukocytesDisease
1995
Progress Towards a Vaccine for Lyme Disease
Telford S, Fikrig E. Progress Towards a Vaccine for Lyme Disease. BioDrugs 1995, 4: 49-60. DOI: 10.1007/bf03259070.Peer-Reviewed Original ResearchLyme diseaseLyme disease vaccineSurface protein AOuter surface protein AProtective immunityPrototype vaccineCareful surveillanceClinical trialsChronic natureDisease vaccineSuch vaccinesMouse modelVaccinated hostAdvanced stageVaccineDiseaseInfectious ticksInfectionAntibodiesProtein AYearsMiceImmunityTrialsEfficacy of Human Lyme Disease Vaccine Formulations in a Mouse Model
Telford SR, Kantor FS, Lobet Y, Barthold SW, Spielman A, Flavell RA, Fikrig E. Efficacy of Human Lyme Disease Vaccine Formulations in a Mouse Model. The Journal Of Infectious Diseases 1995, 171: 1368-1370. PMID: 7751719, DOI: 10.1093/infdis/171.5.1368.Peer-Reviewed Original ResearchConceptsMouse modelC3H/HeJ mouse modelLyme diseaseRecombinant outer surface protein APhase I human trialsPhase II trialSurface protein AUnvaccinated miceII trialVaccinated miceOuter surface protein AVaccine formulationsHuman trialsRecombinant OspAMiceBorrelia burgdorferiDiseaseTrialsMajor siteTrial sitesProtein ATicksImmunizationVaccineInfectionOral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis
Dunne M, al-Ramadi BK, Barthold SW, Flavell RA, Fikrig E. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis. Infection And Immunity 1995, 63: 1611-1614. PMID: 7890431, PMCID: PMC173199, DOI: 10.1128/iai.63.4.1611-1614.1995.Peer-Reviewed Original ResearchConceptsAnti-OspA antibodyMurine Lyme borreliosisDevelopment of antibodiesMajor outer surface proteinsSalmonella typhimurium strainsOral vaccinationIntradermal challengeMouse modelAttenuated strainOuter surface proteinsHigh titersLyme borreliosisLyme diseaseBorrelia burgdorferiTyphimurium strainsCausative agentDiseaseAntibodiesSurface proteinsSalmonella typhimuriumGavageVaccinationMiceTitersBorreliosis